The summary of the research - clinical outcomes and survival differences between primary, secondary and concomitants carcinoma in situ of urinary bladder treated with BCG Immunotherapy is given below.
<h3>What is the summary of the above research?</h3>
Urinary bladder carcinoma in situ (CIS) is a flat, high-grade, and aggressive form of urothelial cancer with a high likelihood of development to muscle-invasive illness and metastatic dissemination.
The study's goal was to compare the clinical histories and survival rates of primary, secondary, and concurrent CIS of the bladder.
Learn more about Immunotherapy:
brainly.com/question/14493516?
#SPJ4
